Clinical Trial Update: Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial compares tofacitinib with methotrexate as the first-line DMARD for rheumatoid arthritis, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Tofacitinib (tofacitinib)

Snippet

Sponsor: Dr. Mohammad Mamun Khan | Conditions: Rheumatoid Arthritis | Phase 4 | Status: UNKNOWN